Literature DB >> 21278717

Hypertension in 2010: Blood pressure and the kidney.

Luis M Ruilope1.   

Abstract

2010 saw the publication of a number of papers that provide new information on the relationship between blood pressure and the kidney. The data reinforce the need for future studies to jointly consider cardiovascular and renal outcomes.

Entities:  

Mesh：

Year:  2011        PMID： 21278717     DOI： 10.1038/nrneph.2010.189

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


  10 in total

1.  Blood pressure control in chronic kidney disease: is less really more?

Authors:  Julia B Lewis
Journal:  J Am Soc Nephrol       Date:  2010-06-24       Impact factor: 10.121

2.  Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.

Authors:  George L Bakris; Pantelis A Sarafidis; Matthew R Weir; Björn Dahlöf; Bertram Pitt; Kenneth Jamerson; Eric J Velazquez; Linda Staikos-Byrne; Roxzana Y Kelly; Victor Shi; Yann-Tong Chiang; Michael A Weber
Journal:  Lancet       Date:  2010-02-18       Impact factor: 79.321

3.  Endothelin receptor antagonists in proteinuric renal disease: every rose has its thorn.

Authors:  Eberhard Ritz; René Wenzel
Journal:  J Am Soc Nephrol       Date:  2010-02-04       Impact factor: 10.121

4.  Cardiovascular events during differing hypertension therapies in patients with diabetes.

Authors:  Michael A Weber; George L Bakris; Kenneth Jamerson; Matthew Weir; Sverre E Kjeldsen; Richard B Devereux; Eric J Velazquez; Björn Dahlöf; Roxzana Y Kelly; Tsushung A Hua; Allen Hester; Bertram Pitt
Journal:  J Am Coll Cardiol       Date:  2010-06-29       Impact factor: 24.094

5.  Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis.

Authors:  Kunihiro Matsushita; Marije van der Velde; Brad C Astor; Mark Woodward; Andrew S Levey; Paul E de Jong; Josef Coresh; Ron T Gansevoort
Journal:  Lancet       Date:  2010-05-17       Impact factor: 79.321

6.  Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.

Authors:  Dick de Zeeuw; Rajiv Agarwal; Michael Amdahl; Paul Audhya; Daniel Coyne; Tushar Garimella; Hans-Henrik Parving; Yili Pritchett; Giuseppe Remuzzi; Eberhard Ritz; Dennis Andress
Journal:  Lancet       Date:  2010-11-06       Impact factor: 79.321

7.  Intensive blood-pressure control in hypertensive chronic kidney disease.

Authors:  Lawrence J Appel; Jackson T Wright; Tom Greene; Lawrence Y Agodoa; Brad C Astor; George L Bakris; William H Cleveland; Jeanne Charleston; Gabriel Contreras; Marquetta L Faulkner; Francis B Gabbai; Jennifer J Gassman; Lee A Hebert; Kenneth A Jamerson; Joel D Kopple; John W Kusek; James P Lash; Janice P Lea; Julia B Lewis; Michael S Lipkowitz; Shaul G Massry; Edgar R Miller; Keith Norris; Robert A Phillips; Velvie A Pogue; Otelio S Randall; Stephen G Rostand; Miroslaw J Smogorzewski; Robert D Toto; Xuelei Wang
Journal:  N Engl J Med       Date:  2010-09-02       Impact factor: 91.245

8.  Effects of intensive blood-pressure control in type 2 diabetes mellitus.

Authors:  William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

9.  Avosentan for overt diabetic nephropathy.

Authors:  Johannes F E Mann; Damian Green; Kenneth Jamerson; Luis M Ruilope; Susan J Kuranoff; Thomas Littke; Giancarlo Viberti
Journal:  J Am Soc Nephrol       Date:  2010-02-18       Impact factor: 10.121

10.  Risk prediction is improved by adding markers of subclinical organ damage to SCORE.

Authors:  Thomas Sehestedt; Jørgen Jeppesen; Tine W Hansen; Kristian Wachtell; Hans Ibsen; Christian Torp-Pedersen; Christian Torp-Petersen; Per Hildebrandt; Michael H Olsen
Journal:  Eur Heart J       Date:  2009-12-23       Impact factor: 29.983
  10 in total
  5 in total

1.  Angiotensin II AT(2) receptor decreases AT(1) receptor expression and function via nitric oxide/cGMP/Sp1 in renal proximal tubule cells from Wistar-Kyoto rats.

Authors:  Jian Yang; Caiyu Chen; Hongmei Ren; Yu Han; Duofen He; Lin Zhou; Ulrich Hopfer; Pedro A Jose; Chunyu Zeng
Journal:  J Hypertens       Date:  2012-06       Impact factor: 4.844

2.  Pathophysiology of hypertension in the absence of nitric oxide/cyclic GMP signaling.

Authors:  Robrecht Thoonen; Patrick Y Sips; Kenneth D Bloch; Emmanuel S Buys
Journal:  Curr Hypertens Rep       Date:  2013-02       Impact factor: 5.369

3.  Assessing murine resistance artery function using pressure myography.

Authors:  Mohd Shahid; Emmanuel S Buys
Journal:  J Vis Exp       Date:  2013-06-07       Impact factor: 1.355

4.  Genetic modifiers of hypertension in soluble guanylate cyclase α1-deficient mice.

Authors:  Emmanuel S Buys; Michael J Raher; Andrew Kirby; Mohd Shahid; Shahid Mohd; David M Baron; Sarah R Hayton; Laurel T Tainsh; Patrick Y Sips; Kristen M Rauwerdink; Qingshang Yan; Robert E T Tainsh; Hannah R Shakartzi; Christine Stevens; Kelly Decaluwé; Maria da Gloria Rodrigues-Machado; Rajeev Malhotra; Johan Van de Voorde; Tong Wang; Peter Brouckaert; Mark J Daly; Kenneth D Bloch
Journal:  J Clin Invest       Date:  2012-05-08       Impact factor: 14.808

5.  Renal nerve ablation reduces blood pressure in resistant hypertension: Long-term clinical outcomes in a single-center experience.

Authors:  Andrea Denegri; Tino Naduvathumuriyil; Thomas Felix Lüscher; Isabella Sudano
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-03-25       Impact factor: 3.738
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.